Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Immunologic Study of Treatment-Naive HIV Patients Starting a Darunavir/Ritonavir- or Efavirenz-Based HAART

This study has been completed.
Information provided by (Responsible Party):
Janssen-Cilag S.p.A. Identifier:
First received: August 23, 2011
Last updated: November 25, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)